其他
2022年10月 | 失败临床研究TOP10
[1] https://ir.tricida.com/news-releases/news-release-details/tricida-reports-topline-results-valor-ckd-phase-3-trial[2]https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-contrast-phase-iii-programme-for-otilimab-in-the-treatment-of-moderate-to-severe-rheumatoid-arthritis/[3]https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-ramp-vs-6766-clinical-trials-and[4] https://www.biospace.com/article/sanofi-drops-program-releases-q3-report/[5] https://www.relmada.com/investors/news/press-releases/detail/269/relmada-therapeutics-announces-top-line-results-from-phase[6] https://invest.clene.com/PressReleases/news-details/2022/Clene-Reports-Topline-Results-Demonstrating-Survival-Signal-for-CNM-Au8-in-Healey-ALS-Platform-Trial/default.aspx[7]https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-new-clinical-and-non-clinical-studies-of-lagevrio-molnupiravir/;https://www.fujifilm.com/jp/en/news/hq/8698;https://mp.weixin.qq.com/s/dmYxbFpG6Il3AEQjluoapA[8] https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-announces-topline-results-catalina-phase-2-trial-ngm621[9] https://www.harbourbiomed.cn/upload/202210/1665363661060118238.pdf?downfile=pdf[10]https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-termination-kvd824-phase-2